Y-mAbs Therapeutics saw the highest growth of 2.99% in patent filings in June and no patents were granted in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.49% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Y-mAbs Therapeutics‘s patent filings and grants. Buy the databook here.
Smarter leaders trust GlobalData
Y-mAbs Therapeutics has been focused on protecting inventions in Australia(AU) with three publications in Q2 2024
The Australia(AU) Patent Office dominates the patent filings with nearly 75% of filings. The Australia(AU), and World Intellectual Property Organization(WIPO) patent Office are among the top ten patent offices where Y-mAbs Therapeutics is filings its patents..
Roche could be the strongest competitor for Y-mAbs Therapeutics
For comprehensive analysis of Y-mAbs Therapeutics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.
Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.
